Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock Holdings Lessened by Deutsche Bank AG

Deutsche Bank AG cut its stake in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) by 18.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 273,811 shares of the company’s stock after selling 61,807 shares during the period. Deutsche Bank AG’s holdings in Akero Therapeutics were worth $7,617,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Sterling Capital Management LLC grew its holdings in shares of Akero Therapeutics by 764.3% during the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company’s stock valued at $50,000 after acquiring an additional 1,582 shares in the last quarter. Quarry LP acquired a new stake in Akero Therapeutics during the fourth quarter valued at $83,000. Summit Investment Advisors Inc. grew its stake in Akero Therapeutics by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock valued at $197,000 after purchasing an additional 450 shares in the last quarter. Hsbc Holdings PLC increased its position in Akero Therapeutics by 8.5% in the 4th quarter. Hsbc Holdings PLC now owns 7,886 shares of the company’s stock worth $220,000 after purchasing an additional 621 shares during the last quarter. Finally, AlphaQuest LLC increased its position in Akero Therapeutics by 32,588.0% in the 4th quarter. AlphaQuest LLC now owns 8,172 shares of the company’s stock worth $227,000 after purchasing an additional 8,147 shares during the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. HC Wainwright lifted their price target on Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a report on Monday, March 3rd. Bank of America upgraded shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Morgan Stanley reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Sunday, March 2nd. UBS Group raised their price target on shares of Akero Therapeutics from $42.00 to $109.00 and gave the company a “buy” rating in a report on Friday, January 31st. Finally, Citigroup reduced their price objective on shares of Akero Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Tuesday, May 13th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $82.33.

Insider Activity

In other news, insider Catriona Yale sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $49.87, for a total transaction of $498,700.00. Following the completion of the transaction, the insider now directly owns 95,648 shares in the company, valued at $4,769,965.76. The trade was a 9.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Cheng sold 30,000 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $41.77, for a total transaction of $1,253,100.00. Following the completion of the sale, the chief executive officer now owns 656,062 shares in the company, valued at approximately $27,403,709.74. The trade was a 4.37% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 219,208 shares of company stock valued at $9,218,994. 7.94% of the stock is owned by insiders.

Akero Therapeutics Trading Down 2.7%

NASDAQ:AKRO opened at $38.87 on Friday. The company’s 50 day moving average is $40.85 and its 200-day moving average is $37.83. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. Akero Therapeutics, Inc. has a 12 month low of $17.86 and a 12 month high of $58.40. The firm has a market cap of $3.10 billion, a price-to-earnings ratio of -10.37 and a beta of -0.12.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Monday, May 12th. The company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.01) by $1.91. Equities analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.